- Business Wire•3 days agoEnanta Pharmaceuticals Announces Data on Eight-Week Treatment of AbbVie’s VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) in Patients with Genotype 1b Chronic Hepatitis C
Enanta Pharmaceuticals, Inc., , a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced new data showing high response rates with just eight weeks of VIEKIRAX® + EXVIERA® treatment.
- PR Newswire•3 days agoAbbVie Presents Data on Eight-Week Treatment of VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) in Patients with Genotype 1b Chronic Hepatitis C
NORTH CHICAGO, Ill., Sept. 23, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced new data showing high response rates with just eight weeks of VIEKIRAX® (ombitasvir/paritaprevir/ritonavir ...
- Zacks•4 days ago
The fact that Allergan (AGN) is willing to shell out as much as up to $1.695 billion for Tobira has led to speculation that more acquisition deals will be announced in this space.
Enanta Pharmaceuticals, Inc. (ENTA)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||25.25 x 200|
|Day's Range||26.34 - 26.85|
|52wk Range||16.75 - 41.77|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||17.45|
|Avg Vol (3m)||282,112|
|Dividend & Yield||N/A (N/A)|